ArticleBMC ophthalmology2026
Phototherapeutic Keratectomy for epithelial basement membrane dystrophy: long-term observation in Chinese patients.
Article in BMC ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
objectiveTo evaluate the short-term and long-term efficacy of Phototherapeutic Keratectomy (PTK) in treating corneal epithelial basement membrane dystrophy (EBMD) and to investigate the factors that influence its outcomes.
methodsThis retrospective case series with prospective outcome evaluation analyzed all patients undergoing PTK for EBMD by a single surgeon at Eye & ENT hospital of Fudan University. Participants unresponsive to pharmacological therapy with recurrent ocular pain from epithelial erosions underwent PTK. Pre- and postoperative analysis included symptomatology, treatments, refractive status, visual acuity and corneal densitometry (CD).
resultsMedical records of 40 patients aged 42.0 ± 13.5 years old were analyzed, with a follow-up duration ranging from 12 to 150 months. The mean ablation depth was 23.1 ± 9.7 μm, with a range of 6-40 μm. PTK significantly alleviated erosion symptoms and reduced the need for medication in both the short and long term postoperatively. A single erosive event was observed in one patient, but no patient warrant reoperation. Best Corrected Visual Acuity (BCVA) improved significantly after surgery, with 87.5% of patients achieving a BCVA of 20/20. No significant hyperopia or myopic shift was observed. CD values at center of the anterior and central strata decreased significantly after PTK (p < 0.05).
conclusionPTK with ablation depth of around 25 μm is a simple and feasible surgical method that effectively mitigates discomfort symptoms in patients with EBMD, minimizes medication reliance, and demonstrates safety and efficacy in long-term follow-up.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.